
|Articles|October 17, 2012
Newer prostate Ca agent shows positive pain outcomes
Recent studies of the oral androgen receptor inhibitor enzalutamide (Xtandi) evaluated the effect of costicosteroid use with the agent as well as its pain-related outcomes in patients with advanced prostate cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves rucaparib for chemotherapy-naïve, BRCA-mutated mCRPC
2
FDA approves flibanserin for hypoactive sexual desire disorder in postmenopausal women
3
Perioperative EV plus pembrolizumab extends survival in cisplatin-eligible MIBC
4
John Michael DiBianco, MD, outlines rationale for the SOUL trial
5

















